Dose Study of ANX1502 in Healthy Volunteers

Key Inclusion Criteria: * Must be healthy as determined by medical evaluation including medical history, physical examination, vital signs assessments (including supine blood pressure, supine pulse rate, respiration rate, and temporal body temperature), 12-lead electrocardiogram (ECG), and laboratory tests. * MAD cohorts only: Documented history of vaccinations within 5 years of Screening or willing to undergo vaccinations prior to Screening against encapsulated bacterial pathogens. Key Exclusion Criteria: * History or presence of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, hematological, or neurological disorders capable of significantly altering the absorption, malabsorption syndrome, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data. Exceptions can be made for individuals with childhood or remote disorders that are no longer active. * History of any autoimmune disease * History of meningitis or septicemia * Clinically significant infection within 30 days prior to study drug administration that required medical intervention * Known genetic deficiencies of the complement cascade system or immunodeficiency. * Clinically significant illness within 4 weeks of the start of dose administration as determined by the Investigator. * Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions . * History of prior other malignancy that could affect compliance with the protocol or interpretation of results * Has clinically significant laboratory abnormalities or abnormal ECG * History of splenectomy. * Antinuclear antibodies titer ≥1:160 at Screening. * Has donated blood or plasma within 30 days prior to Screening or had a loss of whole blood of more than 500 milliliter (mL) within the 30 days prior to Screening, or receipt of a blood transfusion within one year prior to Screening.